Blackfynn Acquires Therapy Potentially Ready for Phase 3 Testing
News
Blackfynn announced that its is acquiring the rights to a candidate Parkinson’s disease treatment that others gave up on but is thought ready to move into pivotal Phase 3 testing. Neither the ... Read more